PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Second Quarter 2025 Results Key Financial Results Revenue: US$14.7b (up 10% from 2Q 2024).

XAU/USD consolidates above the 50-day MA, as softer U.S. data boosts rate cut odds. Gold price future hinges on inflation and ...

Trump has said that tariffs on pharmaceutical imports could reach 250%, the steepest rate he has proposed for the sector. Trump, who in July threatened 200% duties, wants to motivate drug companies to ...

Litecoin (LTC) has surged to $119.30 after breaking key resistance at $116, fueled by record transaction volumes and growing ...

The issuer is solely responsible for the content of this announcement.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Trump demands U.S. drug prices match lowest international rates for some or face executive action. This article originally ...